Nilo Therapeutics launched with a $101 million Series A to translate neuro‑immunology discoveries into therapies that modulate brain‑body circuits to restore immune homeostasis. Backers include Column Group, DCVC Bio and the Gates Foundation; the company will expand R&D and preclinical programs focused on autoimmune and inflammatory diseases. Separately, Beacon Biosignals raised $86 million to build a large brain‑wave dataset intended to accelerate neurological drug discovery and diagnostics. Investors are funding companies that combine biological discovery with large, longitudinal datasets and AI to de‑risk later‑stage programs.